Grifols has met the target enrolment of 339 subjects in the Study of ProlAstin-c Randomized Therapy with Alpha-1 augmentation (SPARTA) Phase III trial to treat emphysema.
The placebo-controlled, double-blind, randomised study is designed to assess the safety and efficacy of 60mg/kg and 120mg/kg doses of Alpha1-Proteinase inhibitor Prolastin-C given once a week against placebo in slowing down the progression of lung tissue loss in emphysema patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Patients with alpha-1-antitrypsin (AAT) deficiency also called alpha-1 are enrolled on the study planned to be carried out across 16 countries and more than 50 centres.
The study will also measure the rate of pulmonary-tissue loss as the primary measure of clinical efficacy. It is determined using whole lung computed tomography (CT) densitometry.
Grifols Clinical Operations senior director Sandra Camprubi said: “While alpha-1 patients currently benefit from recommended AAT augmentation therapy, we hope to show clinical evidence of benefit with the currently approved dose and a greater impact by doubling the single dose to 120mg/kg weekly.
“We look forward to providing topline data from this study in 2026 and evaluating the next regulatory steps to provide emphysema patients impactful treatment options for alpha-1.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSPARTA is claimed to be the largest study on AAT augmentation therapy till now.
With the commitment to support the community of alpha-1, the company introduced AlphaID At Home Genetic Health Risk Service (AlphaID At Home). It is a direct-to-consumer programme in the US to screen for the genetic alpha-1 risk.
